I like this part of a statmentArkady Mandel MD, PhD, DSc, Chief Scientific Officer of Theralase® stated, "Patients with BCG-Unresponsive NMIBC CIS have limited treatment options other than bladder removal surgery. We look forward to discussing the strong, interim clinical data from Study II with the PIs of the study, who are key opinion leaders in the Canadian and US urologic community. The interim clinical data to be presented details the safety and efficacy of Ruvidar™-based photodynamic therapy PDT for the treatment of BCG-Unresponsive NMIBC CIS. The current interim Phase II clinical study analysis demonstrates a significant clinical advantage of the Theralase® technology in the current treatment landscape and provides potential for a novel, effective and lasting treatment option for these patients. Moving forward, we are continuing to advance new patient recruitment with the goal of completing patient recruitment for our Phase II study by year end".